title: A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity.
abstract: The first trial of an anti-HIV immunization, using a recombinant vaccinia virus expressing gp160 (rV) for priming and paraformaldehyde-fixed rV-infected PBLs and soluble gp 160 for boosting, clearly showed an in vitro HIV-protective immune reaction. This result led us to carry out an additional 2 year Phase I clinical trial in 25 HIV-seronegative volunteers, using HIV gp 160 antigens for immunization in four different protocols. The 2 year trial showed (a) the safety of the preparations, (b) a transient humoral immunity following each boost, and (c) a long-lasting memory T-cell response. Memory cytotoxic T-lymphocytes (CTLs) induced by gp 160 antigen with or without vaccinia vector lysed HLA class I restricted target cells expressing HIV-1 env antigens. These results are consistent with CTLs being an effective component of an AIDS vaccine to control cell-to-cell viral replication, dissemination in the organism, and subsequent evolution toward AIDS.
authors.affiliation: Hôpital Saint Antoine, Paris, France.
authors.forename: O
authors.initials: O
authors.lastname: Picard
authors.forename: A
authors.initials: A
authors.lastname: Achour
authors.forename: J
authors.initials: J
authors.lastname: Bernard
authors.forename: A
authors.initials: A
authors.lastname: Halbreich
authors.forename: B
authors.initials: B
authors.lastname: Bizzini
authors.forename: V
authors.initials: V
authors.lastname: Boyer
authors.forename: C
authors.initials: C
authors.lastname: Desgranges
authors.forename: J M
authors.initials: JM
authors.lastname: Bertho
authors.forename: A
authors.initials: A
authors.lastname: Lachgar
authors.forename: B
authors.initials: B
authors.lastname: Polliotti
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000328:Adult; D000595:Amino Acid Sequence; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D015686:Gene Products, env / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D007114:Immunization; D007156:Immunologic Memory; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011498:Protein Precursors / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015488:HIV Antigens; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D014614:Vaccines, Synthetic